Ventrus Biosciences Inc Stock price Nasdaq
Equities
US9228221019
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- USD | 0.00% |
Jan. 19 | Assembly Biosciences Insider Bought Shares Worth $511,264, According to a Recent SEC Filing | MT |
Jan. 04 | Assembly Biosciences, Inc. Provides Anticipated Development Milestones for 2024 | CI |
Financials (USD)
Sales 2023 * | - | Sales 2024 * | - | Capitalization | 72.92M |
---|---|---|---|---|---|
Net income 2023 * | -66M | Net income 2024 * | -81M | EV / Sales 2023 * | - |
Net cash position 2023 * | - | Net cash position 2024 * | - | EV / Sales 2024 * | - |
P/E ratio 2023 * |
-0.93
x | P/E ratio 2024 * |
-0.9
x | Employees | - |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 67.01% |
Latest transcript on Ventrus Biosciences Inc
Managers | Title | Age | Since |
---|---|---|---|
Jason Okazaki
CEO | Chief Executive Officer | 48 | 20-03-29 |
Anuj Gaggar
CTO | Chief Tech/Sci/R&D Officer | - | Nov. 07 |
William Delaney
CTO | Chief Tech/Sci/R&D Officer | 52 | 20-05-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Susan Mahony
BRD | Director/Board Member | 60 | 17-12-13 |
Gina Consylman
BRD | Director/Board Member | 52 | 20-10-19 |
William Ringo
CHM | Chairman | 78 | 14-06-30 |
1st Jan change | Capi. | |
---|---|---|
+13.52% | 9.63B | |
-7.87% | 5.37B | |
+12.50% | 4.28B | |
+18.09% | 3.71B | |
+42.95% | 2.91B | |
-19.01% | 2.54B | |
-20.66% | 2.37B | |
+17.86% | 1.87B | |
-0.50% | 1.64B |
- Stock
- Equities
- Stock Assembly Biosciences, Inc.
- Stock Ventrus Biosciences Inc - Nasdaq